#Singapore #Wemedoo #oomnia #Across Global Alliance

Across Global Alliance Chooses oomnia® by Wemedoo for Central Clinical Trial Management

In a significant move to improve the management of clinical trials, Across Global Alliance has officially appointed Wemedoo's advanced data management system, oomnia®, as its central digital platform. This strategic partnership aims to enhance operational efficiency and regulatory compliance for clinical research across more than 90 countries.

The decision to adopt oomnia® resulted from a comprehensive evaluation process that highlighted its unique capabilities to streamline clinical trial management. Unlike other solutions in the market, oomnia® provides an all-in-one platform integrating critical functions such as Electronic Data Capture (EDC), Clinical Trial Management System (CTMS), Randomization and Trial Supply Management (RTSM), and electronic Trial Master File (eTMF). This integration allows for more efficient and cohesive data workflows, addressing a common problem faced by clinical research organizations where fragmented systems lead to inefficiencies and data silos.

"Managing global clinical trials demands a solution that enables effortless collaboration, reduces delays, and ensures data consistency throughout all operational sites," stated Steven Bukvic, Chair of the Across Global Alliance. With the adoption of oomnia®, he believes they have found a platform that not only meets these rigorous demands but also provides the necessary flexibility to navigate the complexities of clinical research.

Wemedoo AG's CEO, Nina Cihoric, echoed this sentiment, highlighting how this partnership is poised to transform clinical trial management. Cihoric noted, "By implementing a truly integrated and adaptive infrastructure, we relieve alliance members of administrative burdens, allowing them to concentrate on advancing scientific inquiry."

The collaborative synergy of Across Global Alliance and Wemedoo promises to create a framework where the emphasis is on delivering scientific progress rather than grappling with logistical challenges. With oomnia® acting as the backbone of this digital infrastructure, all client and member organizations can expect enhanced clinical trial execution, real-time data quality assessments, and a user-friendly navigation experience.

As one of the leading strategic alliances of clinical research organizations, Across Global Alliance integrates local expertise with a unified operational framework to deliver comprehensive clinical research services across various therapeutic areas. The decision to employ oomnia® signifies an ongoing commitment to achieving operational excellence and maintaining data integrity in global clinical research efforts.

Wemedoo AG is a Swiss-based entity that specializes in offering innovative, data-driven solutions for the healthcare sector. Aiming to merge state-of-the-art technology with substantial clinical insights, Wemedoo enables research teams, CROs, and sponsors to conduct clinical trials more effectively while reducing operational costs and expediting breakthroughs in medical innovation.

This partnership marks a pivotal step forward in the clinical research landscape, underscoring the importance of technological integration in facilitating higher standards of practice and promoting advancements in global health. As countries continue to adapt to the evolving demands of clinical trials, offerings like oomnia® will play an essential role in shaping the future of medical innovation and research efficiency.

For more information about this collaboration, you may reach out to Steven Bukvic at Across Global Alliance or visit the websites of Wemedoo and Across Global Alliance for further insights on their services and technological solutions.

Conclusion

The introduction of oomnia® as the centralized clinical trial infrastructure by Across Global Alliance offers an exemplary model of how technology can enhance global health initiatives. Coordination and compliance will benefit significantly from this strategic move, leading to accelerated progress in clinical research outcomes.